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Abstract
Background: Adaptive model-based dose-finding designs have demonstrated advantages over traditional rule-
based designs but have increased statistical complexity but uptake has been slow especially outside of cancer trials.
TRAFIC is a multi-centre, early phase trial in rheumatoid arthritis incorporating a model-based design.
Methods: A Bayesian adaptive dose-finding phase I trial rolling into a single-arm, single-stage phase II trial. Model
parameters for phase I were chosen via Monte Carlo simulation evaluating objective performance measures under
clinically relevant scenarios and incorporated stopping rules for early termination. Potential designs were further
calibrated utilising dose transition pathways.
Discussion: TRAFIC is an MRC-funded trial of a re-purposed treatment demonstrating that it is possible to design,
fund and implement a model-based phase I trial in a non-cancer population within conventional research funding
tracks and regulatory constraints. The phase I design allows borrowing of information from previous trials, all
accumulated data to be utilised in decision-making, verification of operating characteristics through simulation,
improved understanding for management and oversight teams through dose transition pathways. The rolling
phase II design brings efficiencies in trial conduct including site and monitoring activities and cost.
TRAFIC is the first funded model-based dose-finding trial in inflammatory disease demonstrating that small phase I/
II trials can have an underlying statistical basis for decision-making and interpretation.
Trial registration: Trials Registration: ISRCTN, ISRCTN36667085. Registered on September 26, 2014.
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Background
The development of novel therapies has brought effi-
cient, contemporary statistical model-based dose-finding
designs to assess levels of toxicity and activity. Adaptive
model-based designs for dose-finding studies are based
on making dose recommendations given all accumulated
data at that time. They have demonstrated advantages to
traditional rule-based designs, such as the 3 + 3 design
[1, 2] but have increased statistical complexity with a
historical lack of simulation software resulting in slow
uptake. Adoption has improved within the cancer clin-
ical trial setting but remains poor—only 1.6% of trials
published 1991 to 2006 used model-based approaches
[3] increasing to only 6.4% of trials published 2012 to
2014 [4]. There is a paucity of early phase adaptive
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designs across all fields of medicine. A systematic review
in rheumatology [5] identified just one adaptive early
phase design from 62 trials considered. Rheumatoid
arthritis (RA) afflicts 0.5–1.0% of adults globally, pre-
senting with coincident morbidities including vascular
bone and cognitive deficits which substantially impact
quality of life, disability and long-term survival. Around a
third of patients have stopped working within 2 years of
onset and around a half by 10 years with significant costs
to the economy [6]. Advances in RA management and
biologic therapies have contributed to an improved prog-
nosis but up to 50% fail to achieve remission. Prior thera-
peutics have focussed primarily on immune-based
therapeutics. We sought to evaluate a stromal targeting
strategy, and since this is an entirely novel approach, we re-
quired alternative methods to minimise patient exposure
pending estimation of safety and initial indication of poten-
tial efficacy.
In this paper, we report the statistical design, calibration
and implementation of the Targeting the Rheumatoid
Arthritis Synovial Fibroblast with Cyclin-Dependent Kinase
Inhibition (TRAFIC) trial. TRAFIC is a non-commercial,
multi-centre, phase I/II trial incorporating a Bayesian adap-
tive model-based dose-finding phase I design to determine
the safety, tolerability and efficacy of seliciclib as an addition
to existing therapy in patients with RA. Seliciclib (R-roscov-
itine) is an orally available cyclin-dependent kinase inhibitor
with an acceptable toxicity profile [7] repurposed from the
oncology setting. Determining the toxicity profile of selici-
clib used in combination with a biologic plus or minus con-
ventional synthetic disease-modifying anti-rheumatic drugs
(sDMARDs) is an essential component of TRAFIC, provid-
ing important insight into its potential acceptability as an
adjunctive therapy in RA. Rolling the trial from phase I to
phase II allows site activity and momentum to be retained
bringing trial conduct efficiencies including internal and ex-
ternal trial monitoring activities and associated cost savings.
It also allows continuity for clinical, trial and monitoring
teams. These advantages, and also potential advantages of
‘rolling’ patients from one phase to also contribute to the
next, make this approach attractive when conducting chal-
lenging early phase trials.
Methods
Statistical design
TRAFIC has a phase I dose-finding trial rolling into a
single-arm, single-stage phase II trial. The full trial
protocol has been previously published [8]. The pri-
mary objective of phase I is to determine the maximum
tolerated dose (MTD) of seliciclib over a 4-week treat-
ment period when given in addition to an existing TNF
inhibitor with or without sDMARDs. Phase I is planned
to roll into phase II for which the primary objective is
to assess the potential efficacy of seliciclib following 12
weeks of treatment when administered at the MTD
established in phase I; efficacy is based on a composite
response measure.
Phase I continual reassessment method dose-finding
design
The MTD, based on the occurrence of dose-limiting
toxicities (DLTs), will be established using a modified
one-stage Bayesian continual reassessment method
(CRM) model-based design [9]. A DLT is defined as the
cessation of the Investigational Medicinal Product (IMP)
due to adverse events or reactions (AE/AR) occurring
during the 4-week treatment period. These can be either
symptomatic (e.g. nausea) or abnormal laboratory
parameters or investigations. In addition, a DLT may be
based upon the patient’s request to stop treatment. In
the event of several AEs/ARs contributing to the
decision to discontinue IMP, only a single DLT will be
recorded for that participant. A flare of RA will not be
considered an AE. The MTD is the dose level with an
estimated DLT rate closest to the target DLT rate of
35%, i.e. the dose level that is closest to the level at
which 35% of patients experience a DLT over the treat-
ment period of seliciclib. The definition of a DLT and its
target probability were agreed at a TRAFIC Investigators
consensus meeting as comparable to the rate of sus-
tained tolerated treatment on conventional synthetic
DMARDs such as methotrexate [10].
Phase I will include a maximum of 21 patients. Up to
seven cohorts of three participants each will be treated.
A cohort size of three was chosen as it is logistical to
manage across multi-centres with six planned suspen-
sion periods after each cohort to assess DLT. A cohort
size of one would imply that the trial has to be sus-
pended twenty times to assess DLT, which would make
the trial unfeasibly long. Cohorts of three are a good
compromise for the trial duration and allowing the
model to update frequently with the accruing data. The
number of doses was informed by the oncology experi-
ence which encompasses five dose levels of IMP: partici-
pants will receive either 200mg, 400 mg, 600 mg, 800 mg
or 1000 mg seliciclib daily for 4 consecutive days (one
cycle) every week for 4 weeks. The prior estimate of
MTD is 600 mg (dose level 3) of seliciclib (Table 1) but,
to exercise caution, 400 mg seliciclib (dose level 2) is the
starting dose. The design allows for de-escalation to a
lower dose of 200 mg (dose level 1). The starting dose, a
prior estimate of the MTD, dose range and schedule are
based on healthy control data and oncology experience
[7]. A sample size of 21 patients, from 7 cohorts, is suffi-
cient to identify the expected dose (prior to the trial)
from potential dose escalations from the starting dose,
two de-escalation doses to the estimated dose, plus one
additional confirmatory cohort at the final selected dose,
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resulting in 7 cohorts of 3 patients per cohort. The per-
formance of the design was assessed via simulation.
The recommended dose (the dose with estimated DLT
probability closest to the target of 35%) for each of the
subsequent cohorts is determined using the CRM
incorporating all of the accumulated DLT outcomes but for
added safety, the design includes a restriction to prevent
skipping of untested doses when escalating. Recruitment
continues until either the maximum sample size is reached,
the trial is stopped early due to unacceptable levels of DLT
at the lowest dose or when there are four consecutive
cohorts allocated to the recommended MTD (providing
sufficient evidence that the MTD is reached). The two early
stopping rules allow for early termination:
1. If there is a high probability (> 0.7) that the
posterior probability of DLT at the lowest dose is
greater than the target DLT rate of 35%, indicating
that the lowest dose is too toxic.
2. If four consecutive cohorts (three patients in each
cohort) have already been allocated at the current
MTD, which would also be the recommended dose
level for the next cohort if the trial continued.
The value of 0.7 was selected so that the design will rec-
ommend stopping early for excessive toxicity if we observe
2 or 3 DLTs out of the first 3 patients at the lowest dose
level. This is exemplified in Fig. 1 which shows the dose
transition pathways (DTP) for the first three cohorts. DTP
are utilised (i) as a calibration tool to help evaluate potential
designs and (ii) to visualise projected dose recommenda-
tions for clinical acceptance [11, 12].
In addition, DTP project possible pathways for all subse-
quent cohorts, allowing recruitment to proceed if the
outcome of the final patient within the current cohort does
not alter the dose recommendation for the next cohort. For
TRAFIC, however, to avoid potential bias at trial conduct,
only the next cohort is displayed. If implemented in full, this
Table 1 Prior probability that each Dose Level is the MTD for differing σβ, δ=0.06
Dose level Prior SD of slope parameter β, σβ
0.1 σβ
LI = 0.265 √1.34 =1.16
1 (200mg) 0.01 0.20 0.42
2 (400mg) 0.22 0.19 0.05
3 (600mg) 0.54 0.22 0.05
4 (800mg) 0.22 0.19 0.05
5 (1000mg) 0.01 0.20 0.42
Note: a large σβ does not necessarily correspond to an uninformative prior for MTD level; √1.34 is often chosen as the default value for CRM models. The least
informative value of σβ is one where there are almost equal prior probabilities (chance) that each dose level is the MTD across the 5 dose levels
Fig. 1 Dose transition pathways flow diagram for first three cohorts
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strategy can reduce the operational demands on the trial
management group, including the trial statistician. Decisions
to progress to the next cohort are considered by the TRAF
IC Data Monitoring Committee (DMC) who make recom-
mendations regarding the continuation of the trial.
At trial completion, the number of patients experiencing
DLT at each dose level, together with the proportion of
patients with DLT at that dose level, will be reported. The
Bayesian posterior probability of DLT at each dose level
(with 90% probability interval) will be reported graphically
and in tabular form. The MTD will be reported as well as
the posterior probability that the DLT rate at dose level 1
(200mg) is greater than the target level of 35%. Secondary
outcome measures, including pharmacodynamic (PD) bio-
markers and pharmacokinetic (PK) parameters, will be
presented descriptively and graphically.
Continual reassessment method model details
The one-stage, one parameter Bayesian logistic dose-
toxicity model used in TRAFIC is given by:
ϑ x; βð Þ ¼ exp 3þ e
βx
 
1þ exp 3þ eβxð Þ for−∞ < x < ∞;
where x is the scaled dose and ϑ(x, β) is the probability
of a DLT at dose x [13]. The model parameter β is as-
sumed to be random with prior distribution Nð0; σ2βÞ .
The Bayesian CRM model is completed by a specifica-
tion of the prior probability of a DLT associated with
the five test doses (the skeleton) and σ2β; the prior vari-
ance of β. Early termination is allowed if there is a high
probability that the posterior probability of DLT at the
lowest dose is greater than the target DLT rate. Deter-
mining the posterior distribution of the DLT occurrence
probability at the lowest dose requires the posterior dis-
tribution for β to be evaluated. After the first n patients,
this is given by:





i¼1ϑ xi; βð Þ
yi 1−ϑ xi; βð Þð Þ1−yi ;
where Xn = {x1, x2,…, xn} are the scaled doses and
Yn = {y1, y2,…, yn} are the DLT outcomes (0 or 1).
The posterior probability that the DLT occurrence
probability at dose level 1 is greater than some rate ϑL is
given by
R βL




and xD1 is the scaled dose for dose level 1. The integralR βL
−∞ pðβ jXn;YnÞdβ is analytically intractable and so is
obtained by numerical integration [14].
Calibration of the continual reassessment method design
The Bayesian CRM model is calibrated (specification of
the skeleton and prior variance of β) using the following
algorithm of Cheung [13] which was implemented using
a modified version of the R function mtrials part of the
dfcrm R library [15]:
a) For a given indifference interval half-width δ, the
associated skeleton is obtained using the dfcrm
function getprior. The indifference interval is an
interval into which the DLT probability of the
selected dose will eventually fall given a sufficiently
large sample size.
b) For each δ, the least informative prior standard
deviation for the slope parameter β, σLIβ ðδÞ, is
determined. σβ is defined to be least informative if
the prior probability that a dose level is the MTD is
approximately equal for all dose levels, that is, the
distribution of the MTD (which depends on σβ)
corresponds to the uniform distribution. Thus, σLIβ





, where K is the number of
dose levels. Table 1 shows the effect of varying σβ
for TRAFIC when δ=0.06; a large σβ does not
necessarily correspond to an uninformative prior
for the MTD dose level whereas σLIβ does ensure
almost equal prior probability that each of the five
dose levels is the MTD.
c) The pair {δ, σLIβ (δ)} was chosen based upon the
evaluation of the following performance measures:
(i) the ability to correctly select the true MTD—the
risk-adjusted average accuracy, AN (weighting the
probability of selecting a dose level by the absolute
discrepancy between the true probability of toxicity
at that dose level and the target probability of
toxicity), and the unadjusted probability of correctly
selecting the true MTD; (ii) optimal allocation
defined as the mean proportion of patients treated
within one dose level of the true MTD; (iii) the
mean proportion of patients treated at an overdose
(a dose above the true MTD); and (iv) the mean
number of patients treated [13].
Operating characteristics of the continual reassessment
method design
The performance measures in (c) above were estimated
by Monte Carlo simulation: 20,000 trials were simulated
for different values of δ (0.02 to 0.20 in steps of 0.01).
Trials were simulated assuming the underlying probabil-
ities of DLT (Table 2). These are the appropriate plateau
calibration configurations with five test dose levels when
the target DLT rate is 35% [13]. The performance of the
design also was assessed via simulation under several
clinically relevant scenarios where, firstly, the true prob-
ability of DLT follows the skeleton chosen for TRAFIC
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and, secondly, the MTD is assumed to occur at each of
the remaining four dose levels.
Dose level 1 (200 mg) was thought unlikely to be
efficacious; hence, calibration of the CRM focused on
achieving (1) good accuracy, optimal allocation and
minimising the proportion of patients treated at an over-
dose when the true simulated MTD was at dose levels 2
to 5 and (2) minimising the number of patients treated
when the true MTD was at dose level 1. Performance
measures implementing the early stopping rules 1 and 2
are plotted against δ (Fig. 2) for each of the calibration
curves (Table 2).
The mean of the performance measures taken over the
calibration curves 2, 3, 4 and 5, i.e. when the true simu-
lated MTD is at dose levels 2, 3, 4 and 5 are given in
Table 3 and Fig. 3. The performance measures (1) accur-
acy index AN [13], (2) the unadjusted probability of
selecting the true MTD, (3) the mean proportion of pa-
tients treated at an overdose and (4) the mean propor-
tion of patients treated within 1 dose of the true MTD,
all show a similar relationship with δ. As δ increases, the
measures remain fairly constant until δ=0.06 when they
drop significantly. Except at very low levels of δ, the
mean number of patients treated decreases as δ in-
creases, particularly so when the simulated true MTD is
dose level 1. The variation in AN over the calibration
curves 2, 3, 4 and 5, SD (AN), is smallest when δ=0.04
and remains low until δ exceeds 0.06 when it increases
rapidly. This variation should be low to ensure reason-
able performance across dose levels 2 to 5, as opposed
to a good performance at some doses and poor perform-
ance at others. Given the objective of achieving a balance
between good performance when the true MTD is at
dose levels 2 to 5 and minimising the number of patients
treated when the true MTD is at dose level 1, δ=0.06
was selected.
Simulations to assess the chosen level of δ for
various dose-toxicity relationships (Table 4) assume
both the true probability of DLT follows the skeleton
chosen for TRAFIC (simulation 1) and where the
assumed true MTD across the five dose levels is
varied (simulations 2–6). The performance of the
final proposed CRM design is promising as indicated
by the accuracy index AN which is above 0.90 for
each simulation scenario. The final design parame-
ters are summarised in Table 5.
Phase II Fleming A’Hern design
Phase II is a single-arm, single-stage early phase trial
based on a Fleming-A’Hern design [16] recruiting a total
of 18 patients at the recommended phase II dose who
provided written informed consent, with baseline and
12-week outcome data. Efficacy is assessed via clinical
assessments, analysis of synovial biopsies and contrast-
enhanced MRI of an affected hand and wrist. The pri-
mary outcome measure is a composite response rate at
12 weeks defined as achieving two of the following three
criteria: (i) EULAR moderate response or ACR20 re-
sponse, (ii) histological reduction in macrophage number
in the sub lining layer of the synovium ≥ 20% and (iii)
reduction of Rheumatoid Arthritis MRI Scoring System
score, on MRI, of ≥ 0.5 units or osteitis score of ≥ 0.2
units. Secondary outcome measures are as for phase I
and, additionally, changes in PD biomarkers in synovial
tissue and response rate after 1, 2, 3, 6 and 9 weeks of
therapy.
Response rate will be calculated as the total number
of patients responding as a proportion of all patients
who start treatment. Any patients who are not assess-
able at 12 weeks will be classed as a non-responder.
Individual components of the composite response
outcome will be reported descriptively. Adverse events
will be reported as the number of patients experien-
cing an event as a proportion of the total number of
patients starting treatment, reported descriptively. PK
parameters and PD biomarkers will be presented
graphically.
The Fleming A’Hern design assumes a composite
response rate to reject seliciclib (p0) < 25% and a re-
sponse rate to investigate seliciclib further (p1) > 50%.
The justification to investigate seliciclib further is
based on observing a critical minimum number of re-
sponses, as specified in the statistical analysis plan. As
an early phase trial, the error levels are inflated but
restricted to an acceptable level of < 15% α (type 1)
and < 20% β (type 2). With these stated parameters,
the target recruitment for phase II is calculated as 18
patients.
At the conclusion of phase II, the Fleming A’Hern
design would indicate no further investigation is war-
ranted if the observed number of clinical responses is
less than the critical number, retained in the statistical
trial master file. As this is the first trial investigating
seliciclib in this indication (as a repurposed drug with
a novel mechanism of action), the decision to collate
Table 2 Probability of DLT at each of five dose levels for five
different dose-toxicity curves. Plateau calibration configuration
curves for target DLT probability θ=0.35 and five test dose levels
Curve Dose level
1 2 3 4 5
1 0.35 0.52 0.52 0.52 0.52
2 0.21 0.35 0.52 0.52 0.52
3 0.21 0.21 0.35 0.52 0.52
4 0.21 0.21 0.21 0.35 0.52
5 0.21 0.21 0.21 0.21 0.35
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further phase 2 evidence will also be based on clinically
relevant PD biomarkers and PK parameters, since the
TRAFIC trial management group would not want to
reject a potentially active drug which has not achieved
pragmatic clinical measures of efficacy. Specifically, in
terms of synovial PD biomarkers: (i) TaqMan low-
density transcriptional arrays incorporating genes of
interest relevant to fibroblast biology, inflammation,
cell cycle and apoptosis applied to mRNA extracted
from whole synovial tissue; (ii) PD effects of seliciclib
on the synovial fibroblast; and (iii) markers of cell
proliferation, such as Ki-67.
Fig. 2 Performance measures against the indifference interval half-width, δ, for each of the plateau calibration curves. Early stopping rules are
condition 1 and 2
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Discussion
The TRAFIC trial is the first reported dose-finding trial
using a model-based design in inflammatory disease. It
is a non-commercial, multi-centre, phase I/II early phase
Bayesian adaptive model-based dose-finding trial de-
signed to determine the safety, tolerability and efficacy
of seliciclib as an addition to existing therapy in patients
with RA. There remains a clinical need for novel thera-
peutics or drug repurposing in rheumatoid arthritis
given sub-optimal responses to all available therapies in
a significant proportion of patients. Moreover, the field
needs to be able to make rapid decisions with new
modes of action as early as possible to optimise trial
recruitment. Efficient designs are required to minimise
patient exposure pending estimation of safety. TRAFIC
is a rolling phase I/II trial bringing efficiencies in site ac-
tivity, patient numbers, external monitoring and costs,
minimising some of the challenges when conducting
early phase trials.
There are demonstrated advantages of model-based
designs for determining maximum tolerated dose in
dose-finding studies, but uptake has been slow in disci-
plines outside of cancer trials. The statistical calibration
and implementation of the TRAFIC trial demonstrate
that it is possible to design, fund and implement a
model-based continual reassessment method phase I
trial in a non-cancer population within research funding
and regulatory constraints.
The design allows learning of information from cancer
patients to inform the TRAFIC trial design parameters,
specifically starting dose, prior estimate of the maximum
tolerated dose, dose range and schedule. The Bayesian
continual reassessment method allows all available accu-
mulated data to be utilised to inform decision-making re-
garding dose escalation, de-escalation or retention
through progressive cohorts. The Bayesian continual re-
assessment method also allows prior data to be utilised in
the prior distribution, although TRAFIC conservatively
opted for a least informative skeleton. Simulation allows
the operating characteristics of the proposed adaptive de-
sign to be assessed and the approach in TRAFIC incorpo-
rates two stopping rules. At the design stage, the use of
the dose transition pathways (DTP) encourages closer en-
gagement with the clinical investigators, trials manage-
ment team and statisticians and improves understanding
of how such a model may work in practice. Such discus-
sions are particularly helpful to gather and incorporate
vital clinical opinions in the development and calibration
of the model. Both simulations and DTP play an instru-
mental role in the successful implementation of this
method, which is considerably more complex than a sim-
ple rule-based design such as the 3 + 3. The phase II
Table 3 Summary statistics for the performance measures over the plateau calibration curves 2, 3, 4 and 5 for increasing levels of












0.02 0.46 0.51 0.17 0.79 19.3 0.12
0.03 0.48 0.52 0.17 0.80 20.1 0.06
0.04 0.46 0.51 0.17 0.79 20.3 0.05
0.05 0.46 0.51 0.17 0.78 19.9 0.06
0.06 0.46 0.50 0.16 0.78 19.7 0.06
0.07 0.44 0.48 0.14 0.73 19.5 0.09
0.08 0.43 0.48 0.13 0.73 19.4 0.11
0.09 0.42 0.46 0.13 0.73 19.1 0.12
0.10 0.41 0.45 0.11 0.71 18.9 0.14
0.11 0.39 0.43 0.10 0.70 18.4 0.16
0.12 0.38 0.42 0.10 0.70 18.3 0.17
0.13 0.38 0.42 0.10 0.70 18.2 0.17
0.14 0.37 0.41 0.10 0.69 17.7 0.18
0.15 0.36 0.40 0.09 0.69 17.7 0.19
0.16 0.36 0.40 0.09 0.69 17.6 0.19
0.17 0.36 0.40 0.09 0.69 17.0 0.20
0.18 0.36 0.39 0.09 0.69 17.0 0.21
0.19 0.34 0.38 0.09 0.68 16.4 0.22
0.20 0.32 0.36 0.08 0.66 15.8 0.21
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design of TRAFIC demonstrates that even small, single-
arm trials can have an underlying statistical basis for
decision-making and interpretation, often discounted.
Operationally, identified barriers including longer set-up
time for statistical simulation and trial management im-
plementation are beginning to be addressed through
NIHR and UKCRC training for both clinical and statistical
teams alike [17]. The TRAFIC trial design was supported
through NIHR UKCRC CTU infrastructure funding prior
to protocol development being funded by MRC. There
still remains a need for unified support from regulators
and journal editors to promote more accurate dosing.
Fig. 3 Summary statistics for the performance measures taken over the plateau calibration curves 2, 3, 4 and 5. Performance measures are plotted
against the indifference interval half-width, δ, and shown according to various stopping criteria
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Other operational considerations include managing re-
cruitment to small, fixed cohort sizes across multiple sites,
potential to skip doses and stop early and implementing
efficient Data Monitoring Committee decision-making to
allow smooth movement between cohorts. Implementa-
tion of a dose transition pathway allows a transparent,
graphical interpretation of the trial design to facilitate up-
front discussion and decision-making with clinical teams.
It can enable an efficient look ahead strategy although any
associate bias in doing so must be considered. The dose
transition pathway can provide understanding and guid-
ance to the Data Monitoring Committee and is recom-
mended to facilitate upfront discussion and consensus on
trial conduct.
The rolling design recruiting patients seamlessly from
phase I to phase II allows site activity and momentum to
be retained and also brings trial conduct efficiencies in-
cluding internal site monitoring and external data moni-
toring activities, with obvious cost savings. The rolling
design allows continuity for clinical, trial and monitoring
teams maintaining relationships and consistently high
quality across trial management activities across phases.
A rolling design has the potential advantage to allow pa-
tients in the final cohort in phase 1 to be retained as the
first patients recruited to phase 2, dependent upon the
dose in the final cohort. Altogether, this approach to the
trial design is attractive to clinical, trial and site staff and
efficient in-patient recruitment when conducting challen-
ging early phase trials. The TRAFIC trial demonstrates
that small phase I/II trials can have an underlying statis-
tical basis for decision-making and interpretation. TRAF
IC will follow the CONSORT reporting recommendations
to describe a transparent statistical design reflecting rele-
vant clinical opinion and decision-making.
The re-purposing of drugs across diseases requires re-
dosing and safety assessment and as the potential for
repurposing increases, so does the potential to conduct
trials with model-based designs to more accurately
estimate optimal dosing. The TRAFIC trial is the first
reported dose-finding trial of re-purposed treatment
using a model-based design in inflammatory disease,
conducted within the academic environment within
research funding and regulatory constraints.
Trial status
Protocol v11.00 21-March-2019. Open to recruitment:
March-2015, recruitment completion expected June
2021.
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Table 4 Performance measures for simulated trials
Simulation
scenario



















1 2 3 4 5
1 0.14 0.23 0.35 0.47 0.57 0.91 0.50 0.22 0.95 19.7
2 0.35 0.40 0.50 0.60 0.70 0.93 0.36 0.83 0.67 18.4
3 0.15 0.35 0.40 0.50 0.60 0.92 0.45 0.46 0.88 19.3
4 0.05 0.15 0.35 0.50 0.60 0.93 0.62 0.25 0.97 20.1
5 0.05 0.15 0.25 0.35 0.60 0.92 0.50 0.08 0.78 20.0
6 0.05 0.10 0.20 0.30 0.35 0.93 0.34 0.00 0.53 20.2
Table 5 Final trial design parameters
Clinical parameters DLT definition: cessation of IMP due to AE/AR
Dose set: 200, 400, 600, 800, 1000mg daily
Starting dose: 400 mg
Fixed or variable sample size: fixed, n=21




Model for dose-toxicity curve: Bayesian
logistic regression
Initial MTD prior: 600 mg
One-stage or two-stage design: One
Estimation approach: Bayesian
Skeleton: (0.14, 0.23, 0.35, 0.47, 0.57)
Model: one parameter Bayesian model with




Early stopping rules: Yes
i) High probability (> 0.7) that posterior
probability of DLT at lowest dose is greater
than target DLT of 35%, indicating that the
lowest dose is too toxic
ii) 4 consecutive cohorts allocated MTD,
providing sufficient evidence MTD is reached
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